IP Library › Granted Patent US 12703692
Granted Patent B2
US 12703692 · App. 19/224,208 · Granted Aug 11, 2026

Small molecule inhibitors of mammalian SLC6A19 function

Inventors: Dean G. Brown (Hollis, NH); Giovanni Muncipinto (Cambridge, MA); Joshua Ethan Zweig (Somerville, MA); Long Vo Nguyen (Boston, MA); Mitchell T. Antalek (Medford, MA); Ryan A. Hollibaugh (Quincy, MA)
Assignee: Jnana Therapeutics Inc.
C07D401/04A61K31/44A61K31/4523A61K31/4525A61K31/453A61K31/4535A61K31/454A61K31/4545A61K31/497A61K31/501A61K31/506A61K31/5377C07D211/58C07D401/06C07D401/14C07D403/04C07D405/06C07D405/14C07D409/06C07D409/14C07D413/04C07D413/06C07D413/12C07D413/14C07D417/04C07D417/06C07D417/14C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703692
App. No.
19/224,208
Granted
Aug 11, 2026
Kind
B2
Abstract

Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.

Claims (47)

1 . A compound of Formula (I):

wherein:

n is 1;

L 1 is -alkyl-;

L 2 is absent;

L 3 is —C(O)—;

X 1 and X 2 are independently selected from —H and cycloalkyl; provided that X 1 and X 2 are not both —H;

Y 1 is unsubstituted or substituted aryl;

Y 2 is selected from hydroxyalkyl and —NH(Y 2 ′);

Y 2 ′ is alkyl; and

Y 3 , Y 4 , Y 5 , and Y 6 are independently selected from —H, and halide;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein any one of the following statements (A)-(B) applies:

(A) Y 1 is selected from

(B) Y 1 is selected from

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

Y 1 is selected from

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein L 1 is —CH 2 —.

5 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein L 1 is —CH 2 —.

6 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein L 1 is —CH 2 —.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are independently selected from —H and cyclopropyl; provided that X 1 and X 2 are not both —H.

8 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are independently selected from —H and cyclopropyl; provided that X 1 and X 2 are not both —H.

9 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are independently selected from —H and cyclopropyl; provided that X 1 and X 2 are not both —H.

10 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 are independently selected from —H and cyclopropyl; provided that X 1 and X 2 are not both —H.

11 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

Y 1 is

and

R 1 , R 2 , R 3 , R 4 , and R 5 are independently selected from —H, —F, —Cl, —Br, —CN, —CH 3 , —CH 2 CH 3 , —OCF 3 , and

12 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

13 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

14 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

15 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

16 . The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

17 . The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is selected from hydroxyalkyl having 1 to 3 carbons and —NH (Y 2 ′).

18 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

19 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

20 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

21 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

22 . The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

23 . The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

24 . The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein Y 2 ′ is alkyl having 1 to 3 carbons.

25 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.

26 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.

27 . The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.

28 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.

29 . The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.

30 . The compound of claim 11 , or a pharmaceutically acceptable salt thereof, wherein Y 2 is hydroxyalkyl having 1 to 3 carbons.